Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Sudden cardiac death risk is sharply elevated in people with diabetes

The risk of sudden cardiac death is higher both for people with type 1 and type 2 diabetes, according to a large study published in the European Heart Journal today (Thursday). The increase in risk is especially noticeable among younger adults.

3 Dec 2025

Diabetes drugs linked to slower frailty progression in older adults

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.

3 Dec 2025

Obesity-driven estrone emerges as a key driver of deadly postmenopausal breast cancer

A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in post-menopausal women with obesity.

2 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025

Brain recordings reveal why food cravings return despite tirzepatide

Researchers investigate the effects of tirzepatide on food preoccupation by influencing the brain’s mesolimbic circuitry.

1 Dec 2025

Stopping GLP-1 drugs before pregnancy leads to more weight gain

Researchers determine the risk of pregnancy weight gain in patients who were prescribed GLP-1 RAs prior to conception.

1 Dec 2025

Semaglutide helps older adults lose weight without immediate bone loss

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to assess its effects on bone health.

1 Dec 2025

Regenerative medicine offers a pathway toward curing type 1 diabetes

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

26 Nov 2025

Obesity-related metabolic stress may affect brain health far earlier than expected

For decades, scientists have known that what harms the body often harms the brain. Conditions such as obesity, high blood pressure and insulin resistance strain the body's vascular and metabolic systems.

25 Nov 2025

GLP-1 discontinuation associated with more weight gain and pregnancy complications

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.

24 Nov 2025

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.

23 Nov 2025

Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in an individual taking tirzepatide. They found that a delta–theta biomarker disappeared during symptom-free periods and re-emerged weeks before relapse, suggesting a possible neural marker of vulnerability to dysregulated eating.

18 Nov 2025

Brain recordings reveal short-lived effects of tirzepatide on food cravings

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" thought to be involved in food noise – but only temporarily.

17 Nov 2025